Vaccinex Reports 2025 Annual Financial Results

Vaccinex (OTCMKTS: VCNX) reported it released its 2025 annual financial results for the year ended December 31, 2025 and posted the financial statements on its website on April 29, 2026.

Rhea-AI Summary

Vaccinex (OTCMKTS: VCNX) reported it released its 2025 annual financial results for the year ended December 31, 2025 and posted the financial statements on its website on April 29, 2026. The company is a clinical-stage developer of investigational antibody therapies for Alzheimer’s, Huntington’s, and cancer.

Argus May 1 session

+28.70% close to close Open Argus

Details

News Market Reaction – VCNX

In the May 1 session, VCNX gained 28.70%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +28.7% in the session following this news. A strong positive reaction aligns with p...

Analysis

The stock surged +28.7% in the session following this news. A strong positive reaction aligns with prior interest around Vaccinex’s Alzheimer’s and Huntington’s programs, but would exceed the typical -1.58% average move seen after past earnings. Investors previously focused on cash levels, net losses, and listing compliance. Any outsized upside could face risks if financial pressures persist or if expectations for future financings and trial milestones are not met in subsequent disclosures.

Key Figures

Fiscal year: 2025

Fiscal year

2025

Year ended December 31, 2025 for reported annual results

Previous Earnings Reports

2 past events · Latest: Nov 18

Same Type 2 events

1. Nov 18

   Q3 2024 earnings

   24h Move

   -1.6%

   Reported Q3 loss, low cash, financing steps, and Nasdaq compliance issues.

2. May 15

   Q1 2024 earnings

   24h Move

   -1.6%

   Q1 financials, reduced R&D and net loss amid Nasdaq non-compliance notice.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

alzheimer’s

1 terms

alzheimer’s medical

"pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and cancer"

A progressive brain disorder that slowly erodes memory, thinking and the ability to perform everyday tasks, often described like a computer whose files and programs are gradually corrupted. It matters to investors because the disease drives demand for diagnostics, treatments and care services, influences regulatory decisions and trial outcomes, and creates large market opportunities as well as high clinical and regulatory risk for companies developing therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website.

About Vaccinex, Inc.

Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including neurodegenerative diseases, cancer, and autoimmune disorders, and is currently initiating a new Phase 2b study in Alzheimer’s disease. Vaccinex is based in Rochester, New York.

Investor Contact
Elizabeth Evans, PhD
Chief Operating Officer, Vaccinex, Inc.
(585) 271-2700
eevans@vaccinex.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vaccinex (VCNX) announce on April 29, 2026 about its 2025 results?

Vaccinex announced it released its 2025 annual financial results and posted statements on its website. According to Vaccinex, the financial statements for the year ended December 31, 2025 are available online for investor review and download.

How can investors access Vaccinex (VCNX) 2025 financial statements?

Investors can access the 2025 financial statements on Vaccinex's investor website where filings are posted. According to Vaccinex, the company posted the complete financial statements for the year ended December 31, 2025 on its website for public access.

Does the Vaccinex (VCNX) announcement include 2025 revenue or earnings figures?

The announcement does not include specific revenue, EPS, or guidance figures in the press text. According to Vaccinex, detailed financials are contained within the posted statements on the company website for review.

What clinical programs does Vaccinex (VCNX) note in the 2025 release?

Vaccinex describes itself as a clinical-stage company working on investigational antibody therapies for Alzheimer’s, Huntington’s disease, and cancer. According to Vaccinex, these therapeutic areas represent the focus of its clinical-stage development programs.

When is Vaccinex's fiscal year end and which period do the posted statements cover?

Vaccinex's fiscal year ended December 31, 2025, and the posted statements cover that full year. According to Vaccinex, the financial statements reflect results and balances for the year ended December 31, 2025.